SARS CoV 2 News and Research

RSS

Experimental vaccine induces neutralizing antibodies against SARS-CoV-2

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine.

15 Jul 2020

Transmission of coronavirus from dogs to humans is scientifically flawed

A study published earlier this year claiming the coronavirus may have jumped from dogs to humans is scientifically flawed, offering no direct evidence to support its conclusions, according to a collaborative group of international researchers, including scientists at the University of Colorado Anschutz Medical Campus.

15 Jul 2020

Viral load peaks in early stages of COVID-19 disease, shows study

In a retrospective study, investigators from New York University Langone Health found that the quantity of SARS-CoV-2 (viral load) collected from patients in the emergency department is significantly higher in patients with fewer or milder symptoms who did not require hospitalization--the opposite of what might be expected.

15 Jul 2020

Certain antibodies may cause the dangerous part of COVID-19 disease

A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.

15 Jul 2020

Study: Amount of SARS-Cov-2 receptor is increased in patients with pre-existing cardiac conditions

Nearly 20% of all COVID-19-associated deaths are from cardiac complications, yet the mechanisms from which these complications arise have remained a topic of debate in the cardiology community.

15 Jul 2020

Mobility and flexibility in SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in July 2020 describes the use of in silico modeling of potential drug targets on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein structures, using data retrieved from the Protein Databank (PDB).

15 Jul 2020

Strong evidence several FDA approved drugs block SARS-CoV-2 in relevant cell-lines and human organoids

Now, a new study describes how compounds that restore the normal transcriptional conditions following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be used to reduce viral load without neutralizing the virus entry into the host cell.

15 Jul 2020

"Winter is coming," warn UK COVID-19 experts

The famous line from "Game of Thrones" about approaching dangers this winter may prove to be accurate, say, scientists in a new report. The researchers state that a second wave of infection could hit the United Kingdom this winter, and this would be worse than the first wave taking as many as 120,000 lives.

14 Jul 2020

A special air filtration system that can "catch and kill" the coronavirus

Now researchers from the University of Houston have come up with a unique air filter system that can catch and kill the novel coronavirus. The air filter can reportedly kill the coronavirus on contact.

14 Jul 2020

Llama nanobodies block SARS-CoV-2 infection in vitro

Now, a team of scientists at the United Kingdom's Rosalind Franklin Institute may have a surprising solution for the coronavirus pandemic, which has killed more than 574,000 people worldwide.

14 Jul 2020

One in three young adults at a higher risk of severe COVID-19 due to smoking, vaping

Now, a new study shows that about one in three young adults may be at risk of severe COVID-19 due to smoking and vaping habits.

14 Jul 2020

Genome comparisons between SARS-CoV-2 and other betacoronaviruses yield applicable insights

Researchers from the Venezuelan Institute for Scientific Research and the Australian National University untangle the mutational and recombinational history of the SARS-2 lineage of betacoronaviruses and their metagenomes with the use of published genomic sequences. Their findings are currently available on the bioRxiv preprint server.

14 Jul 2020

Cold sensitivity of SARS-CoV-2 could impact vaccine studies

Researchers at Duke University in Durham, USA, have made an important discovery about the spike protein on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have a broad impact on vaccine studies.

14 Jul 2020

Investigational antidepressant PT150 shows antiviral activity against SARS-CoV-2

In a recent bioRxiv study, an ad hoc multi-institutional research team from the US shows that a novel hormone receptor modulator PT150 has unique and possibly additive antiviral and immunomodulatory effects – highlighting its potential role in the treatment and prophylaxis of coronavirus disease (COVID-19).

14 Jul 2020

COVID-19 may have an impact on the central nervous system of patients

Depressed mood or anxiety exhibited in COVID-19 patients may possibly be a sign the virus affects the central nervous system, according to an international study led by a University of Cincinnati College of Medicine researcher.

14 Jul 2020

Tobacco smoking and vaping nicotine may exacerbate COVID-19 inflammation

Researchers in San Diego have conducted a study showing that both smoking and the use of e-cigarettes containing nicotine and flavorings may critically exacerbate inflammation in cases of coronavirus disease 2019 (COVID-19) and significantly worsen clinical outcomes.

14 Jul 2020

Keck Medicine of USC participates in clinical trial to evaluate antiviral drug as possible COVID-19 treatment

Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial to evaluate the safety and efficacy of an antiviral drug, DAS181, as a possible treatment for hospitalized patients with severe COVID-19.

14 Jul 2020

Avacta and Integumen team up for detection of novel coronavirus in waste water

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Integumen plc (“Integumen”) to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert system to warn of localized COVID-19 outbreaks.

From Avacta Life Sciences Ltd. 14 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

Saliva promising alternative to upper airway swabs for diagnosis of SARS-CoV-2

The standard diagnostic test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the reverse transcriptase-polymerase chain reaction (RT-PCR) assay. Now, a new study published on the preprint server medRxiv* in July 2020 describes the use of saliva as a sample in RT-PCR for diagnosis in place of nasopharyngeal or oropharyngeal swabs.

14 Jul 2020